Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAK-105 in Healthy Subjects
NCT04964258Phase 1Completed
- Sponsor
- Takeda
- Start
- Jul 2021
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-105-a in nausea ((none)) and Vomiting (4 arms), sponsored by Takeda. Primary endpoint: Number of Participants With At Least One Treatment-emergent Adverse Event at Day 82. Started Jul 2021; status: completed.
02
Drugs
TAK-105-a
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on NCT04964258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04964258.